The NHS’ long term survival is at stake – the Ten Year Plan demonstrates the government’s commitment to invest in its recovery, but in order to truly tackle the existential issues at the heart of the ...

A biennial prize fund to promote thought leadership around the big questions affecting health economics. OHE’s educational ...

In August 2022, President Biden signed the Inflation Reduction Act (IRA) into law. In this OHE Insight, Amanda Cole explores the expert discussions had at ISPOR US 2023.

This is part 2 of the insight series which explores how progress towards an effective pull incentive for antibiotics can be made in Europe.

Our latest research shows respiratory infections cost UK businesses £44 billion a year. Workplace vaccination programs and health-focused policies could help boost productivity, reduce costs, and ...

Insight 3 of this series provides an exploration of revenue guarantee/subscription models and how they could be implemented in the EU.

We dust off last year’s model to consider the potential savings to the NHS from more people going vegan, with a focus on COVID-19.

Rare Disease Day is observed on the last day of February every year, and today – February 29th – is truly the rarest day.

Today marks Rare Disease Day 2025. This time last year we published an Article entitled “ Why do we care about rare?”, summarising the origins of rare disease day, the fundamental ambition – to strive ...

There has never been a more exciting time to be a health economist. The future of health economics is about improving upon what we have and expanding the bounds of what is possible.

Adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond the healthcare system are monetised.

Gene therapies represent a paradigm shift in medicine, with the potential to address the root causes of chronic diseases. They offer one-time treatment regimens and, in some cases, potentially a cure.